Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-03-04 00:00:00 ET · period of report 2024-02-29 · accession 0001415889-24-006474 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-04 | 2024-03-01 | PCVX | Eydelman Mikhail | SVP, GEN COUNSEL, CORP SEC | M - OptEx | $21.41 | +1,667 | 32.9K | +5% | +$35.7K |
| DM | 2024-03-04 | 2024-03-01 | PCVX | Eydelman Mikhail | SVP, GEN COUNSEL, CORP SEC | S - Sale+OE | $73.73 | -1,667 | 31.7K | -5% | -$122.9K |
| D | 2024-03-04 | 2024-03-02 | PCVX | Eydelman Mikhail | SVP, GEN COUNSEL, CORP SEC | F - Tax | $71.55 | -613 | 30.6K | -2% | -$43.9K |
| D | 2024-03-04 | 2024-02-29 | PCVX | Eydelman Mikhail | SVP, GEN COUNSEL, CORP SEC | A - Grant | $0.00 | +10.5K | 31.2K | +51% | $0 |
| D | 2024-03-04 | 2024-02-29 | PCVX | Eydelman Mikhail | SVP, GEN COUNSEL, CORP SEC | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
| D | 2024-03-04 | 2024-03-01 | PCVX | Eydelman Mikhail | SVP, GEN COUNSEL, CORP SEC | M - OptEx | $0.00 | -1,667 | 190.0K | -0.9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-01 | M | A | 1,667 | $21.41 | 32,877 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-01 | S | D | 519 | $73.03 | 32,358 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.325. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2024-03-01 | S | D | 445 | $74.77 | 31,210 | D | — | — | (F5) The price reported is a weighted-average price. The shares were sold at prices ranging from $74.55 to $74.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2024-03-02 | F | D | 613 | $71.55 | 30,597 | D | — | — | (F6) Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. |
| 5 | Common | Common Stock | 2024-02-29 | A | A | 10,500 | $0.00 | 31,210 | D | — | — | (F1) Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 6 | Common | Common Stock | 2024-03-01 | S | D | 703 | $73.59 | 31,655 | D | — | — | (F4) The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $73.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 7 | Derivative | Stock Option (right to buy) | 2024-02-29 | A | A | 50,000 | $0.00 | 50,000 | D | $73.82 · — to 2034-02-28 | 50,000 Common Stock | (F7) 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 8 | Derivative | Stock Option (right to buy) | 2024-03-01 | M | D | 1,667 | $0.00 | 189,999 | D | $21.41 · — to 2032-05-08 | 1,667 Common Stock | (F8) 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. |